We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mirum Pharmaceuticals Inc | NASDAQ:MIRM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.03 | -0.12% | 24.46 | 20.81 | 25.92 | 24.785 | 24.17 | 24.43 | 268,335 | 01:00:00 |
From Apr 2021 to Apr 2024
By Colin Kellaher
Mirum Pharmaceuticals Inc. on Tuesday said it signed an exclusive licensing agreement with Takeda Pharmaceutical Co. for maralixibat for rare pediatric liver diseases in Japan.
Mirum, a Foster City, Calif., biopharmaceutical company, said Takeda would be responsible for development, regulatory approval and commercialization of maralixibat in Japan for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia.
The U.S. Food and Drug Administration is currently reviewing Mirum's application for maralixibat to treat cholestatic pruritus, or itch, in patients with Alagille syndrome, with a target action date of Sept. 29.
Mirum, which earlier this month filed for European approval of maralixibat to treat cholestatic liver disease in patients with Alagille syndrome, said it is looking for partners outside the U.S. and Europe to expand the drug's global reach.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 21, 2021 08:39 ET (12:39 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Mirum Pharmaceuticals Chart |
1 Month Mirum Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
